Blinatumomab Added to Consolidation Chemotherapy Improves OS in Newly Diagnosed ALL in MRD-Negative Remission
Results from the ECOG-ACRIN E1910 Randomized Phase 3 Trial
Results from the ECOG-ACRIN E1910 Randomized Phase 3 Trial
The addition of blinatumomab to consolidation chemotherapy resulted in an improved overall survival (OS) in patients with newly diagnosed B-lineage acute lymphoblastic leukemia (ALL), according to study findings presented at the 2022 ASH Annual Meeting & Exposition by Mark Litzow, MD, Mayo Clinic, Rochester, MN.
The phase 3 trial randomized patients to receive conventional chemotherapy with or without blinatumomab to determine if patients who become MRD-negative (<0.01%) after induction chemotherapy would have improved outcomes with the addition of blinatumomab.
The addition of blinatumomab to consolidation chemotherapy resulted in a significantly better OS in patients with newly diagnosed B-lineage ALL who were MRD negative after intensification chemotherapy. No significant safety concerns were noted.
Source:
Litzow M, Sun Z, Paietta E et al. Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial. Presented at the ASH Annual Meeting & Exposition; December 10-13, 2022; New Orleans, LA, and virtual. LBA-1.
